Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voxalatamab in advanced solid tumors
NCT03926013Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2019
- Primary completion
- Aug 2021
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of voxalatamab in metastatic castration-resistant prostate cancer (mCRPC) and renal cell carcinoma (RCC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability at 3 years, Number of Participants with Dose-Limiting Toxicity (DLT) at 3 years and 1 more. Started May 2019; status: completed.
02
Drugs
voxalatamab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03926013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926013.